Atea Pharmaceuticals, Inc.
A Boston drug developer that makes oral antiviral medicines for serious viral infections, with its lead program pairing bemnifosbuvir and ruzasvir against hepatitis C. It was founded in 2012 by Jean-Pierre Sommadossi, a co-founder of Pharmasset, the company behind the hepatitis C treatment sofosbuvir, sold as Sovaldi. Sommadossi helped build that earlier drug, and Atea carries forward the same nucleoside antiviral science.
Granted 573.0K
Granted 114.9K
Granted 29.6K
Granted 42.1K
Granted 29.6K
Granted 58.0K
Granted 29.6K
Granted 29.6K · Bought 6.1K
Granted 51.3K
Granted 29.6K
Granted 29.6K
Granted 41.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Sommadossi Jean-PierrePresident, CEO, and Chairman, Director · 3 transactions | +7.6% | 6.63M | 573.0K | — | — |
| Corcoran AndreaSee Remarks · 3 transactions | +13.9% | 823.6K | 114.9K | — | — |
| Berger Franklin MDirector · 1 transaction | +5.8% | 536.1K | 29.6K | — | — |
| Vavricka JohnChief Commercial Officer · 2 transactions | +31.3% | 176.7K | 42.1K | — | — |
| Lucidi BrunoDirector · 1 transaction | +26.3% | 142.3K | 29.6K | — | — |
| Hammond Janet MJChief Development Officer · 2 transactions | +33.6% | 127.7K | 58.0K | — | — |
| Polsky BruceDirector · 1 transaction | +31.1% | 124.8K | 29.6K | — | — |
| Murphy Polly A.Director · 2 transactions | +41.5% | 121.7K | 29.6K | 6.1K | — |
| Horga Maria ArantxaChief Medical Officer · 2 transactions | +66.9% | 112.2K | 51.3K | — | — |
| Adams Jerome M.Director · 1 transaction | +47.2% | 92.3K | 29.6K | — | — |
| Duncan Barbara GayleDirector · 1 transaction | +47.2% | 92.3K | 29.6K | — | — |
| Foster WayneEVP, Chief Accounting Officer · 2 transactions | +82.5% | 91.5K | 41.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +6.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.